The Fibromyalgia Treatment Market, in the next 10 years, is expected to substantiate. Hospital decision support solutions are being floated, and the status quo is expected to stay the same even going forward. Herein, value propositions are made to the society on the whole and patients in particular by the government, private insurance companies, and social security organizations working in unison. As such, the healthcare industry is expected to witness a good number of clinical outcomes in the forthcoming period.
Strong product pipeline and increasing occurrence of fibromyalgia are the major factors that are projected to boost demand for fibromyalgia treatment over the coming years. Fibromyalgia is characterized by musculoskeletal pain along with anxiety, depression, headaches, irritable bowel syndrome, memory and mood issues, sleep disorders, and fatigue. It is accepted that fibromyalgia modifies the pain sensation mechanism controlled by the brain. As indicated by the National Institute of Health (NIH), around 1.5 billion individuals experienced chronic pain in 2016. Unhealthy lifestyles, sub-optimal diets, and undesirable lack of physical exercise are broadly increasing the danger of chronic pain. Different factors such as rising instances of rheumatic diseases, unmet medical needs, growing awareness among the population, rising geriatric population, and increasing popularity of Chinese therapy options are driving development of the market.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32455
Key players are concentrating on research & development activities to present new products in the market and provide more treatment options. Launch and approval of new fibromyalgia treatment drugs are anticipated to aid market expansion in future.
The global fibromyalgia treatment market is estimated to be valued at US$ 1.2 Bn in 2021, and is expected to exhibit a CAGR of around 7% over the forecast period (2021 – 2031).
Company Profiles:
- Pfizer, Inc.
- Eli Lilly and Company
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd
- Sanofi
- GlaxoSmithKline plc.
- Bayer AG
- TONIX Pharmaceuticals Holdings Corp
- Virios Therapeutics, Inc.
- Aptinyx Inc.
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/32455
Key Takeaways from Market Study
- Under products, anticonvulsants hold the highest value in the market, as they help provide relief from pain and treat the same for a long term.
- By distribution channel, hospital pharmacies hold a notable revenue share of around 46%.
- North America accounted for a share of over 40% in 2020 to become the most lucrative among all regions, and is expected to show significant growth over the next ten years.
- Europe is the next dominating region with a market share of 20% in 2020, due to well-developed medical infrastructure largely supported by governments in the region.
“Increasing burden of chronic pain, rising incidence of traumatic stress and road accidents, growing awareness among the population, and increasing research & development activities are all expected to drive market growth,” says a Persistence Market Research analyst.
Collaborations and Acquisitions – Imperative Strategy for Market Players
Major companies are actively engaging in acquisitions and expansion in order to enhance their product portfolios and outreach to a large number of customers. Globally, leading companies, in order to maintain their market position, follow the trend of acquiring companies who are facing a large number of product recalls.
- In May 2020, AbbVie acquired Allergan plc, which helped the company broaden its existing portfolio and strengthen its presence in the global biopharmaceutical sector.
- In October 2020, FDS BioSciences, Inc. acquired a U.S.-based company, Prismic Pharmaceuticals, which is engaged in developing novel therapies for fibromyalgia treatment.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32455
What else is in the report?
Persistence Market Research offers a unique perspective and actionable insights on the fibromyalgia treatment market in its latest study, presenting historical demand assessment of 2016-2020 and projections for 2021-2031, based on product (anti-depressants, anticonvulsants, muscle relaxants, and analgesics) and distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online sales), across seven key regions of the world.
Related Reports:
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com